Slide 1: Exchange filing cover letter: Investor Presentation
Ref. No.: WOCK/SEC/SE/2021-22/136 8th March, 2022 BSE Limited National Stock Exchange of India Limited Corporate Relations Department Exchange Plaza P J Towers Bandra Kurla Complex Dalal Street Bandra (E) Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 532300 NSE Symbol: WOCKPHARMA Dear Sir/Madam, Sub
Slide 2: Project Liberty: Opportunity to invest in US pharma business
Project Liberty Opportunity to invest in US pharma business Investors Presentation 2022
Slide 3: Safe harbor
Safe harbor The Wockhardt Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, a rights issue of its equity shares and has filed a Letter of Offer. The Letter of Offer is available on the website of the SEBI at https://www.sebi.gov.in, the webs
Slide 4: Snapshot of Wockhardt
Snapshot of Wockhardt Net Sales Revenues INR 2,575 Cr 12 manufacturing facilities across world (9M FY22) EBITDA INR 331 Cr 3 R&D centres one each in India, UK, USA (9M FY22) Profit after tax Over 520 scientists with over 80 PhD’s; INR 32 Cr Drug Discovery team > 150 associates (9M FY22) ~ 5,400 empl
Slide 5: Financial highlights
Financial highlights Net Sales Revenues in INR Cr. EBITDA in INR Cr. 24% YOY growth 331 2,844 2,708 2,575 245 -47 FY 19-20 FY 20-21 9M FY 21-22 FY 19-20 FY 20-21 9M FY 21-22 PAT (Continued operations) after exceptional items in INR Cr. Reduction in long term debts* in INR Cr. 32 -138 -296 2,045 1,25
Slide 6: Net Debt : Equity @ 0.34
Net Debt : Equity @ 0.34* Total Equity increased by >INR 700 Cr. ; Total Borrowings Reduction by > INR 1,000 Cr. Total Equity INR Cr. Total Borrowings INR Cr.* 3,760 3,774 3,057 2,632 1,853 1,569 FY 19-20 FY 20-21 9M FY 21-22 FY 19-20 FY 20-21 9M FY 21-22 Cash & cash equivalents and other Bank balan
Slide 7: Future Growth drivers
Future Growth drivers 5 years growth drivers 1 Novel drug discovery 2 years growth drivers 2 Diabetes Biosimilars in US & Europe 1 Vaccines - Focus on COVID-19 Vaccines 2 Diabetes Biosimilars for Emerging markets 3 Re-organized business structure & leadership Strictly confidential | Page 6
Slide 8: Growth drivers: Vaccines - Focus on COVID-19 Vaccines
Growth drivers for next 2 years 1 Vaccines - Focus on COVID-19 Vaccines Global CMO Supply to UK Govt. >100 Mn Doses supplied Flexibility of supplies from Fill-finish supply of Astra existing India & UK sites Zeneca / University of Oxford COVID-19 Vaccine to UK Govt. Strictly confidential | Page 7
Slide 9: Growth drivers: Diabetes Biosimilars for Emerging markets
Growth drivers for next 2 years 2 Diabetes Biosimilars for Emerging markets Focus on Recombinant Human Insulin and Insulin Glargine in emerging markets API + Low cost manufacturing Manufacturing infrastructure ready Formulation Registered in emerging markets > 25 Under registration in 12 countries m
Slide 10: Growth drivers: Re-organized business structure & leadership
Growth drivers for next 2 years: 3 Re-organized business structure & leadership A Renew leadership B Focus markets Emerging UK India USA markets C Wockhardt selected by Indian Government’s Production Linked Incentive (PLI) Scheme Strictly confidential | Page 9
Slide 11: Novel drug discovery – focus on Antibiotics against resistant infections
Growth drivers for next 5 years 1 Novel drug discovery – focus on Antibiotics against resistant infections 6 QIDP* grant from US FDA for Wockhardt’s 6 novel antibiotics WCK 5222 (Cephalosporin + β-lactam enhancer) - Destination therapy for XDR Gram Negative Acinetobacter & Pseudomonas Pre-clinical P
Slide 12: WCK 5222 differentiation
WCK 5222 differentiation Activity against resistant infection Pipeline Drugs Approved Drugs WCK Product Product Product Product Product Product Product Product Product Organism/ Resistance Mech. 52221 1 2 3 4 5 6 7 8 9 K. pneumoniae (ESβL) K. pneumoniae (KPC) K. pneumoniae (MβL) In E. coli (PBP3 ins
Slide 13: Novel drug discovery pipeline – focus on Antibiotics against resistant infections
Novel drug discovery pipeline – focus on Antibiotics against resistant infections Robust product pipeline Development Stage Target market 1 Emrok IV / Emrok O Launched in India Emerging Markets Partnered with 2 WCK 4873 Phase III Emerging Markets Jemincare for Greater China 3 WCK 4282 Phase III Glob
Slide 14: Growth drivers: Diabetes Biosimilars for US & Europe
Growth drivers for next 5 years 2 Diabetes Biosimilars for US & Europe Biosimilars Portfolio of Insulin & GLP-1 analogs Product Type Development Stage 1 Insulin Glargine Long acting analogue GMP batches for Clinical 2 Insulin Aspart Rapid acting analogue Product developed / Under testing 3 Insulin L
Slide 15: Leadership Team
Leadership Team Ravi Limaye Ajay Sahni Dr. Mahesh Patel Managing Director- Wockhardt UK Managing Director -Wockhardt Bio Chief Scientific Officer AG / France / Pinewood Dr. Habil Khorakhiwala Founder and Executive Chairman Prakash Gupta Lalit Aggarwal Pradnya Deshmukh Dr. Vijayesh Gupta President-Gl
Slide 16: Board of Directors
Board of Directors Mr. Aman Mehta Mr. D. S. Brar Dr. Sanjaya Baru Independent Director Independent Director Independent Director ► Past Head of HSBC operations in India ► Ex-CEO & MD, Ranbaxy Laboratories ► Ex-Official spokesman PMO ► Over 35 years of experience ► Founder of GVK Biosciences Pvt. Ltd
Slide 17: Abbreviations
Abbreviations • API: Active Pharmaceutical Ingredient • CMO: Contract Manufacturing Organization • EBITDA: Earnings before Interest, Tax, Depreciation and Amortization • GLP-1: Glucagon like Peptide-1 • GMP: Good Manufacturing Practice • KOL: Key Opinion Leader • MDR: Multi Drug Resistant • MIC: Min
Slide 18: Life wins !
Life wins ! Impacting Life Saving Life Affordability Stakeholders Strictly confidential | Page 17